Castle Biosciences outlines 2026 revenue target of $340M-$350M as AdvanceAD-Tx launch supports growth strategy
Source: SeekingAlpha
2026-02-26 20:58:41 ET
More on Castle Biosciences
- Castle Biosciences, Inc. (CSTL) Q4 2025 Earnings Call Transcript
- Castle Biosciences Q4 2025 Earnings Preview
- Seeking Alpha’s Quant Rating on Castle Biosciences
- Historical earnings data for Castle Biosciences
- Financial information for Castle Biosciences
Read the full article on Seeking Alpha
For further details see:
Castle Biosciences outlines 2026 revenue target of $340M-$350M as AdvanceAD-Tx launch supports growth strategy
Castle Biosciences Inc.
NASDAQ: CSTL
CSTL Trading
-2.78% G/L:
$27.435 Last:
79,336 Volume:
$27.23 Open:
CSTL Latest News
March 09, 2026 07:00:00 am
DecisionDx®-Melanoma's i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk
March 04, 2026 04:30:00 pm
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma's i31-SLNB, Identifying T1b-T2a Melanoma Patients Who May Safely Avoid SLNB
March 03, 2026 04:30:00 pm
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas
CSTL Stock Data
$948,047,644
27,291,396
0.3%
60
N/A
Medical Diagnostics & Screening
Healthcare
US
Friendswood
